Novel Targets For Atherosclerosis Prevention

What's New with TG and AngPTL3 - Aruna D. Pradhan, MD, MPH, MSc

What’s New with Lp(a) - Samia Mora, MD

What's New with LDL and ApoB - Jorge Plutzky, MD

What's New with Inflammatory Targets - Paul M. Ridker, MD, MPH

Discussion/Q&A - John F. Keaney, Jr., MD - Moderator

Peripheral Arterial Disease

PAD – Pathways for Optimizing Cardiovascular and Limb Outcomes - Marc P. Bonaca, MD, MPH

Discussion/Q&A - Marie D. Gerhard-Herman, MD - Moderator

Heart Failure

Heart Failure and Venous Thromboembolism - Samuel Z. Goldhaber, MD

More Than Just Diabetes and Heart Failure – SGLT2 - Deepak L. Bhatt, MD, MPH

More Than Just Diabetes and Heart Failure – GLP1 - Brendan M. Everett, MD, MPH

Heart Failure – Reduced Ejection Fraction - Marc A. Pfeffer, MD, PhD

Discussion/Q&A - Akshay Suvas Desai, MD, MPH - Moderator

Heart Failure – Preserved Ejection Fraction - Scott D. Solomon, PhD

Heart Failure – Middle-of-the-Road Ejection Fraction – Navigating the Alphabet Soup - Michele A. Hamilton, MD

CMR Imaging of Imaging of Heart Failure - Raymond Y. Kwong, MD, MPH

Atrial Fibrillation & Coronary Disease

Dual Antiplatelet Therapy and Anticoagulation - Michelle L. O'Donoghue, MD, MPH

How to Manage the Anticoagulation Around Ablation and Cardioversions and Watchmans for AF - Bruce A. Koplan, MD

Anticoagulation

Dose-Reduced Direct Oral Anticoagulants – Efficacy and Safety - Behnood Bikdeli, MD, MS

Duration of Anticoagulation – Arterial Thrombosis – Navigating Limitations in Data and Variations in Practice - Teresa Carman, MD, RPVI, MSVM

Duration of Anticoagulation – Venous Thrombosis - Gregory Piazza, MD, MS

Novel Anticoagulation Targets – Factor XI and XII Inhibitors - Jeffrey I. Weitz, MD

Discussion/Q&A - Samuel Z. Goldhaber, MD - Moderator

Racial Disparities In Arterial And Venous Thrombosis

Racial Disparities in Healthcare - Cassandra M. Pierre, MD, MSc

Racial Disparities in Arterial and Venous Thrombosis - Karlyn A. Martin, MD

Discussion/Q&A - Gregory Piazza, MD, MS - Moderator

Genetics

VTE Prediction – Using Genetics as a Powerful Tool - Nicholas A. Marston, MD, MPH

Clonal Hematopoiesis of Indeterminate Potential (CHIP) – Association with VTE & PAD - Peter Libby, MD

Discussion/Q&A - Gregory Piazza, MD, MS - Moderator

Covid And Thrombosis

COVID and Thrombosis – Mechanisms and Epidemiology - Gregory Piazza, MD, MS

Prevention of VTE in COVID-19 Patients - Behnood Bikdeli, MD, MS

Discussion/Q&A - Samuel Z. Goldhaber, MD - Moderator

VTE Prevention

VTE Prophylaxis for Orthopedic Surgery - Samuel Z. Goldhaber, MD

Discussion/Q&A - Ebrahim Barkoudah, MD, MPH - Moderator

PE Reperfusion

Device Therapy for PE Reperfusion – Navigating a Rapidly Changing Landscape - Gregory Piazza, MD, MS

Systemic Fibrinolysis (PEITHO-3) - Samuel Z. Goldhaber, MD

Adventures with Hypertrophic Cardiomyopathy – 1958-2022 - Eugene Braunwald, MD

Pulmonary Hypertension and Thrombosis

Chronic Thromboembolic Pulmonary Hypertension - Bradley A. Maron, MD

Pulmonary Hypertension After PE That is Not Chronic Thromboembolic Pulmonary Hypertension - Jane A. Leopold, MD, FACC, FAHA, FSCAIc

Post-Thrombotic Syndrome

Post-thrombotic Syndrome – Epidemiology and Medical Therapy - Susan R. Kahn, MD, MSc, FRCPC, ABIM

Intervention, Acute Intervention, and Chronic Venous Obstructive Disease - Suresh Vedantham, MD

Discussion/Q&A - Arvind K. Pandey, MD - Moderator

VTE and Cancer

Vascular Cardio-Oncology - Javid Moslehi, MD

Prevention of Thrombotic Complications of Cancer and Cancer Therapy - Simon Mantha, MD, MPH

Treatment of Cancer-Associated Thrombosis - Michael B. Streiff, MD

Discussion/Q&A - Jean Connors, MD - Moderator